Long Non-coding RNAs Regulation of Therapeutic Resistance

Overview

Journal Cancer Drug Resist

Date 2022 May 18

PMID 35582574

Authors

Susan Tsang

Tajhal Patel

Jason T Yustein

Affiliations

Soon will be listed here.

Abstract

Non-protein coding RNAs have emerged as a regulator of cell signaling and cancer progression through regulation of cell proliferation, metastatic burden, and cancer stem cell capacity. A subtype of non-protein coding RNA is long non-protein coding RNA (lncRNA). Besides their aforementioned roles in cancer cell biology, dysregulation of lncRNAs contribute to resistance to therapeutic treatments. A couple of important therapeutic classes are chemotherapy and targeted/hormone therapies. This review highlights the variety of malignancies affected by lncRNA dysregulation and the underlying mechanism causing therapeutic resistance.

Citing Articles

Non-Coding RNAs: Uncharted Mediators of Thyroid Cancer Pathogenesis.

Tabatabaeian H, Yang S, Tay Y Cancers (Basel). 2020; 12(11).

PMID: 33158279 PMC: 7694276. DOI: 10.3390/cancers12113264.

References

Cheng N, Cai W, Ren S, Li X, Wang Q, Pan H . Long non-coding RNA UCA1 induces non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway in EGFR-mutant non-small cell lung cancer. Oncotarget. 2015; 6(27):23582-93. PMC: 4695138. DOI: 10.18632/oncotarget.4361. View

Yao H, He G, Yan S, Chen C, Song L, Rosol T . Triple-negative breast cancer: is there a treatment on the horizon?. Oncotarget. 2016; 8(1):1913-1924. PMC: 5352107. DOI: 10.18632/oncotarget.12284. View

Chen X, Xie R, Gu P, Huang M, Han J, Dong W . Long Noncoding RNA Inhibits Self-Renewal and Chemoresistance of Bladder Cancer Stem Cells through Epigenetic Silencing of SOX2. Clin Cancer Res. 2018; 25(4):1389-1403. DOI: 10.1158/1078-0432.CCR-18-1656. View

Ivery M, Le T . Modeling the interaction of paclitaxel with beta-tubulin. Oncol Res. 2003; 14(1):1-19. DOI: 10.3727/000000003108748568. View

Wang X, Yang B, Ma B . The UCA1/miR-204/Sirt1 axis modulates docetaxel sensitivity of prostate cancer cells. Cancer Chemother Pharmacol. 2016; 78(5):1025-1031. DOI: 10.1007/s00280-016-3158-8. View

Attard G, Parker C, Eeles R, Schroder F, Tomlins S, Tannock I . Prostate cancer. Lancet. 2015; 387(10013):70-82. DOI: 10.1016/S0140-6736(14)61947-4. View

Zhou H, Ma Y, Zhong D, Yang L . Knockdown of lncRNA HOXD-AS1 suppresses proliferation, migration and invasion and enhances cisplatin sensitivity of glioma cells by sponging miR-204. Biomed Pharmacother. 2019; 112:108633. DOI: 10.1016/j.biopha.2019.108633. View

Plunkett W, Huang P, Xu Y, Heinemann V, Grunewald R, Gandhi V . Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol. 1995; 22(4 Suppl 11):3-10. View

Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith R . Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006; 5(10):835-44. DOI: 10.1038/nrd2130. View

10.

Guo S, Chen W, Luo Y, Ren F, Zhong T, Rong M . Clinical implication of long non-coding RNA NEAT1 expression in hepatocellular carcinoma patients. Int J Clin Exp Pathol. 2015; 8(5):5395-402. PMC: 4503113. View

11.

Kamat A, Hahn N, Efstathiou J, Lerner S, Malmstrom P, Choi W . Bladder cancer. Lancet. 2016; 388(10061):2796-2810. DOI: 10.1016/S0140-6736(16)30512-8. View

12.

Sastre J, Garcia-Saenz J, Diaz-Rubio E . Chemotherapy for gastric cancer. World J Gastroenterol. 2006; 12(2):204-13. PMC: 4066028. DOI: 10.3748/wjg.v12.i2.204. View

13.

Hoelder S, Clarke P, Workman P . Discovery of small molecule cancer drugs: successes, challenges and opportunities. Mol Oncol. 2012; 6(2):155-76. PMC: 3476506. DOI: 10.1016/j.molonc.2012.02.004. View

14.

Fan C, Oh D, Wessels L, Weigelt B, Nuyten D, Nobel A . Concordance among gene-expression-based predictors for breast cancer. N Engl J Med. 2006; 355(6):560-9. DOI: 10.1056/NEJMoa052933. View

15.

Zhang C, Zhu K, Ma X . Antisense lncRNA FOXC2-AS1 promotes doxorubicin resistance in osteosarcoma by increasing the expression of FOXC2. Cancer Lett. 2017; 396:66-75. DOI: 10.1016/j.canlet.2017.03.018. View

16.

Han J, Han B, Wu X, Hao J, Dong X, Shen Q . Knockdown of lncRNA H19 restores chemo-sensitivity in paclitaxel-resistant triple-negative breast cancer through triggering apoptosis and regulating Akt signaling pathway. Toxicol Appl Pharmacol. 2018; 359:55-61. DOI: 10.1016/j.taap.2018.09.018. View

17.

An Q, Zhou L, Xu N . Long noncoding RNA FOXD2-AS1 accelerates the gemcitabine-resistance of bladder cancer by sponging miR-143. Biomed Pharmacother. 2018; 103:415-420. DOI: 10.1016/j.biopha.2018.03.138. View

18.

Gloss B, Dinger M . Realizing the significance of noncoding functionality in clinical genomics. Exp Mol Med. 2018; 50(8):1-8. PMC: 6082831. DOI: 10.1038/s12276-018-0087-0. View

19.

Xu W, He L, Li Y, Tan Y, Zhang F, Xu H . Silencing of lncRNA ZFAS1 inhibits malignancies by blocking Wnt/β-catenin signaling in gastric cancer cells. Biosci Biotechnol Biochem. 2018; 82(3):456-465. DOI: 10.1080/09168451.2018.1431518. View

20.

Ma G, Zhu J, Liu F, Yang Y . Long Noncoding RNA LINC00460 Promotes the Gefitinib Resistance of Nonsmall Cell Lung Cancer Through Epidermal Growth Factor Receptor by Sponging miR-769-5p. DNA Cell Biol. 2019; 38(2):176-183. PMC: 6383575. DOI: 10.1089/dna.2018.4462. View